Is Hims & Hers Health a Millionaire Maker? [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
After a recent decline, the stock is down more than 25% from its high. Yet Hims & Hers is still up nearly 200% over the past 12 months. The company has made headlines for selling compounded versions of GLP-1 agonists, the popular diabetes and weight loss drugs revolutionizing the obesity epidemic. On the one hand, its impressive business performance can make investors ponder potential life-changing investment returns. Conversely, feeling confident in Hims & Hers Health can sometimes be challenging. The constant GLP-1 agonist drama surrounding the company, competitive threats, and volatile share prices can be off-putting. So, is Hims & Hers Health a millionaire maker? Or will the stock's 2024 success run out? Here is what you need to know. More than GLP-1 agonists Hims & Hers Health is a direct-to-consumer telehealth platform. People can access (without insurance) digital consultations with healthcare professionals for various conditions, receive prescriptions, and have produ
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health, Inc. (NYSE: HIMS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $42.00 price target on the stock.MarketBeat
- Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]Yahoo! Finance
- HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further? [Yahoo! Finance]Yahoo! Finance
- The Shape of America 2024: Hims & Hers Shares an In-Depth Look Into How Americans Feel About WeightBusiness Wire
HIMS
Earnings
- 11/4/24 - Beat
HIMS
Sec Filings
- 1/2/25 - Form 144
- 12/30/24 - Form 4
- 12/27/24 - Form 4
- HIMS's page on the SEC website